Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2010

View Archived Issues

Denufosol improves lung function in patients with cystic fibrosis

Lixivaptan evaluated vs. furosemide in healthy volunteers

Tirofiban shows safety/preliminary efficacy in BAO and stroke

Merck & Co. claims new neuropeptide S receptor antagonists

New immunoprophylactic antibacterial CLDC+MPF combination presented

Aclidinium bromide shows preliminary efficacy in COPD

NeuroSearch discloses new GABA(A) receptor modulators

Lilly claims new hedgehog signaling inhibitors

New FABP inhibitors presented

MDX-1097 is evaluated in phase I trial in multiple myeloma

Phase I trial data presented on GSK-923295 in solid tumors

GlaxoSmithKline discloses highlights of first quarter 2010

PolyMedix completes phase Ib trial of PMX-60056 for reversal of heparin action

Ascenta and sanofi-aventis sign license agreement in oncology

Scancell and ImmuneRegen BioSciences form strategic alliance

H4 receptor antagonist UR-63325 yields favorable first-in-human data

AstraZeneca submits Axanum MAA in E.U.

Bausch and Lomb acquires Zirgan ophthalmic gel from Sirion

TauRx and Bayer Schering enter into AD collaboration

Preliminary phase III data reported on oral insulin spray

Janssen expands licensing agreement for tapentadol

FDA grants orphan drug status to GVAX CML vaccine

CombinatoRx receives milestone payment for Prednisporin

Grifols to acquire Talecris Biotherapeutics

TK therapy R&D project receives grant from Regione Lombardia

FDA accepts DM-1796 NDA for postherpetic neuralgia

Phase III trial of plitidepsin initiated in multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...